Intuitive Surgical (ISRG) has witnessed a
decline of 10.1% in the last 4 weeks. However,
upwardly revised quarterly earnings expectations and a forthcoming release of
quarterly earnings could bring a dietary recovery. Although safety and cybersecurity issues have caused a 3% slide, analysts believe that the stock is ready to
recover. The stock's mid-case target is observed at $850, indicting potential growth. While Intuitive Surgical experienced
share price weakness recently, the company's
strong earnings and
growing recurring revenue could indicate a shift. The
da Vinci 5 rollout is causing a buzz among hedge funds, adjusting the company's valuation. Furthermore, despite a larger drop compared to the general market, Intuitive Surgical's position as a
leader in robotic-assisted surgery maintains its edge. The company is also recognized for improving
surgical precision through AI. Some investors believe that despite some weaknesses, it is not too late to consider buying Intuitive Surgical. Setbacks aside, growth is expected, with
surging da Vinci usage and new FDA approvals fostering optimism.
Intuitive Surgical ISRG News Analytics from Fri, 03 Oct 2025 07:00:00 GMT to Sat, 18 Apr 2026 19:22:02 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 7
